Abstract: The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the rate of disease progression in a subject having a neurodegenerative disorder, selecting a subject for treatment of a neurodegenerative disorder, selecting a subject for participation in a clinical study, and determining the efficacy of treatment of a neurodegenerative disorder. These methods include determining the level of one or more microRNAs and/or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16? or CD14+CD16? monocyte) or in cerebrospinal fluid (CSF) from the subject and comparing the level of the one or more microRNAs and/or the level of the one or more inflammatory markers with a reference level(s).

Abstract: Methods of treating inflammatory diseases, e.g., diseases associated with inflammatory CD14+/CD16? monocytes, e.g., amyotrophic lateral sclerosis (ALS), stroke, and glaucoma, using compounds such as small molecules and antibodies that target CCR2 or CCL2.

Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.

Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.

Abstract: Methods of treating, reducing the risk of developing, or delaying the onset of an inflammatory disease are disclosed. The methods involved providing a subject with or at risk of developing an inflammatory disease and administering to the subject an effective amount of a first therapeutic composition comprising miR-124. Further provided are methods of diagnosing a subject with or at risk of developing an inflammatory disease.

Abstract: Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARP-1).

Abstract: Methods for increasing the generation of IL-17-producing T cells (TH17) in vivo and in vitro, and enriched populations of TH17 cells for the treatment of diseases benefiting from an induced or enhanced immune response, e.g., infection and cancer.

Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.

Abstract: There is disclosed an integrated project management and risk management system. A risk processor has access to a project data store containing a plurality of inter-related project actions used for project management purposes, and a risk data store which contains a plurality of inter-related project activities and associated risk indicators used for related risk management purposes. The risk processor is operable to generate and write to the risk data store changes to the project activities and risk indicators reflecting changes in the project actions, to generate or receive mitigating activities identified to reduce or prevent a risk or the consequences of a risk associated with a project activity and to write corresponding project action changes to the project data store.

Abstract: Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a neurodegenerative autoimmune disorder such as Multiple Sclerosis are contemplated utilizing proteosomes and/or Glatiramer Acetate, wherein the GA is in a submicron emulsion or a nanoemulsion.

Abstract: Generation of qualified sales leads and market research data comprises use of an interactive device at a first commercial location by a customer of a particular vendor. Customer information is input into the interactive device and that information can be—but need not be—related with a pre-existing record of information about the customer maintained by the particular vendor. The customer interacts with the device to be presented with information about goods or services of another vendor or to permit capture of market research data. The customer receives a coupon that is immediately redeemable for value against goods or services at the particular vendor for having so-interacted with the device. Additional methods that generate such leads and data are also described.

Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.

Abstract: Novel compositions containing an amyloid-? peptide (A?) and methods of using these compositions for treating and preventing A? protein related (e.g., an amyloid fibril) disorders such as Alzheimer's disease are described herein. Also described herein are methods for identifying a vaccine, and methods of vaccinating a patient with an A? peptide composition identified using the methods described herein.

Abstract: This invention pertains to an improvement in the treatment of autoimmune diseases. More specifically, the invention is directed to the use of bystander antigens (i.e. antigens that suppress cells involved in the autoimmune process) for the treatment of autoimmune diseases. The invention also includes pharmaceutical formulations comprising bystander antigens useful in the treatment of autoimmune diseases in mammals.

Abstract: Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.

Abstract: There is disclosed an integrated project management and risk management system. A risk processor has access to a project data store containing a plurality of inter-related project actions used for project management purposes, and a risk data store which contains a plurality of inter-related project activities and associated risk indicators used for related risk management purposes. The risk processor is operable to generate and write to the risk data store changes to the project activities and risk indicators reflecting changes in the project actions, to generate or receive mitigating activities identified to reduce or prevent a risk or the consequences of a risk associated with a project activity and to write corresponding project action changes to the project data store.